These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 25382022)

  • 1. Diagnostic performances of FDG-PET/CT and diffusion-weighted imaging indices for differentiating benign pheochromocytoma from other benign adrenal tumors.
    Nakajo M; Nakajo M; Fukukura Y; Jinguji M; Shindo T; Nakabeppu Y; Kamimura K; Yoneyama T; Takumi K; Yoshiura T
    Abdom Imaging; 2015 Aug; 40(6):1655-65. PubMed ID: 25382022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG-PET/CT and FLT-PET/CT for differentiating between lipid-poor benign and malignant adrenal tumours.
    Nakajo M; Jinguji M; Fukukura Y; Kajiya Y; Tani A; Nakajo M; Nakabeppu Y; Arimura H; Nishio Y; Nakamura F; Yoshiura T
    Eur Radiol; 2015 Dec; 25(12):3696-705. PubMed ID: 25925356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas.
    Imani F; Agopian VG; Auerbach MS; Walter MA; Imani F; Benz MR; Dumont RA; Lai CK; Czernin JG; Yeh MW
    J Nucl Med; 2009 Apr; 50(4):513-9. PubMed ID: 19289420
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Zhou W; Wen J; Hua F; Xu W; Lu X; Yin B; Geng D; Guan Y
    Eur J Radiol; 2018 Jul; 104():26-32. PubMed ID: 29857862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of lipid-rich adrenal tumors by FDG PET/CT: Are they hormone-secreting or not?
    Takanami K; Kaneta T; Morimoto R; Satoh F; Nakamura Y; Takase K; Takahashi S
    Ann Nucl Med; 2014 Feb; 28(2):145-53. PubMed ID: 24272068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADC histogram analysis for adrenal tumor histogram analysis of apparent diffusion coefficient in differentiating adrenal adenoma from pheochromocytoma.
    Umanodan T; Fukukura Y; Kumagae Y; Shindo T; Nakajo M; Takumi K; Nakajo M; Hakamada H; Umanodan A; Yoshiura T
    J Magn Reson Imaging; 2017 Apr; 45(4):1195-1203. PubMed ID: 27571307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
    Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
    Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
    Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
    Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current generation time-of-flight (18)F-FDG PET/CT provides higher SUVs for normal adrenal glands, while maintaining an accurate characterization of benign and malignant glands.
    Koopman D; van Dalen JA; Stigt JA; Slump CH; Knollema S; Jager PL
    Ann Nucl Med; 2016 Feb; 30(2):145-52. PubMed ID: 26644009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adrenal-to-liver SUV ratio is the best parameter for differentiation of adrenal metastases from adenomas using 18F-FDG PET/CT.
    Watanabe H; Kanematsu M; Goshima S; Kondo H; Kawada H; Noda Y; Moriyama N
    Ann Nucl Med; 2013 Aug; 27(7):648-53. PubMed ID: 23625579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between standardized uptake value and apparent diffusion coefficient of neoplastic lesions evaluated with whole-body simultaneous hybrid PET/MRI.
    Rakheja R; Chandarana H; DeMello L; Jackson K; Geppert C; Faul D; Glielmi C; Friedman KP
    AJR Am J Roentgenol; 2013 Nov; 201(5):1115-9. PubMed ID: 24147485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of intratumoral heterogeneity of (18)F-FDG uptake to differentiate between primary benign and malignant musculoskeletal tumours on PET/CT.
    Nakajo M; Nakajo M; Jinguji M; Fukukura Y; Nakabeppu Y; Tani A; Yoshiura T
    Br J Radiol; 2015; 88(1055):20150552. PubMed ID: 26337605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffusion-weighted magnetic resonance imaging in metastatic gastrointestinal stromal tumor (GIST): a pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CT.
    Schmidt S; Dunet V; Koehli M; Montemurro M; Meuli R; Prior JO
    Acta Radiol; 2013 Oct; 54(8):837-42. PubMed ID: 23761549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adrenal tracer uptake by
    Noordzij W; Glaudemans AWJM; Schaafsma M; van der Horst-Schrivers ANA; Slart RHJA; van Beek AP; Kerstens MN
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1560-1566. PubMed ID: 31011769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amide proton transfer-weighted imaging to differentiate malignant from benign pulmonary lesions: Comparison with diffusion-weighted imaging and FDG-PET/CT.
    Ohno Y; Kishida Y; Seki S; Yui M; Miyazaki M; Koyama H; Yoshikawa T
    J Magn Reson Imaging; 2018 Apr; 47(4):1013-1021. PubMed ID: 28799280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative characterization of indeterminate large adrenal masses with dual tracer PET-CT using fluorine-18 fluorodeoxyglucose and gallium-68-DOTANOC: initial results.
    Naswa N; Sharma P; Soundararajan R; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
    Diagn Interv Radiol; 2013; 19(4):294-8. PubMed ID: 23439252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What parameters from 18F-FDG PET/CT are useful in evaluation of adrenal lesions?
    Kunikowska J; Matyskiel R; Toutounchi S; Grabowska-Derlatka L; Koperski L; Królicki L
    Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2273-80. PubMed ID: 25027709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A stepwise approach using metabolic volume and SUVmax to differentiate malignancy and dysplasia from benign colonic uptakes on 18F-FDG PET/CT.
    Oh JR; Min JJ; Song HC; Chong A; Kim GE; Choi C; Seo JH; Bom HS
    Clin Nucl Med; 2012 Jun; 37(6):e134-40. PubMed ID: 22614211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
    Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
    Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy.
    Ohno Y; Koyama H; Yoshikawa T; Matsumoto K; Aoyama N; Onishi Y; Sugimura K
    AJR Am J Roentgenol; 2012 Jan; 198(1):75-82. PubMed ID: 22194481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.